INS and Insulin resistance: Mechanistically, SGLT2 blockade reduces renal glucose reuptake, induces glycosuria, and lowers plasma glucose levels through an insulin-independent mechanism, an important advantage in patients with impaired β-cell function or insulin resistance [84].